Showing results (511-520 of 561) with videos related to
Sort By:
Pageof 57
Allergy|January 1, 1996
Tilarin in combination with astemizoleD A Bukstein, R M Biondi, M M Blumenthal, et al.Journal of Bacteriology|July 27, 2000
AnkB, a periplasmic ankyrin-like protein in Pseudomonas aeruginosa, is required for optimal catalase B (KatB) activity and resistance to hydrogen peroxideM L Howell, E Alsabbagh, J F Ma, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2018
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn J Howie, Nancy S Scher, Laleh Amiri-Kordestani, et al.Biorxiv : the Preprint Server for Biology|April 15, 2024
Quinoline-based compounds can inhibit diverse enzymes that act on DNAJujun Zhou, Qin Chen, Ren Ren, et al.Proceedings of the National Academy of Sciences of the United States of America|September 19, 2024
Naturalized species drive functional trait shifts in plant communitiesMagda Garbowski, Daniel C Laughlin, Dana M Blumenthal, et al.Biorxiv : the Preprint Server for Biology|March 13, 2026
Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cellsMeigen Yu, Puspa Das, John R Horton, et al.The New Phytologist|June 24, 2025
Why are non-native plants successful? Consistently fast economic traits and novel origin jointly explain abundance across US ecoregionsDana M Blumenthal, Jeffrey Diez, Ian Pearse, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmEmily Y Jen, Xin Gao, Liang Li, et al.The Lancet. Oncology|January 24, 2018
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysisJulia A Beaver, Maitreyee Hazarika, Flora Mulkey, et al.Clinical Pharmacology and Therapeutics|February 24, 2018
Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a DiseaseRobert N Schuck, Janet Woodcock, Issam Zineh, et al.Pageof 57